Neoadjuvant therapy of locally advanced gastric cancer
β Scribed by James J. Mezhir; Laura H. Tang; Daniel G. Coit
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 305 KB
- Volume
- 101
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Treatment of gastric cancer has evolved with the advent of randomized trials demonstrating chemotherapeutic agents with efficacy in advanced disease. Level I evidence supports delivering chemotherapy in the neoadjuvant setting; the data shows improvement in progressionβfree and overall survival. A clinical response to therapy is associated with improved R0 resection rates, pathologic response, and outcome in patients with locally advanced disease. Early assessment of metabolic response to therapy can potentially be utilized to tailor treatment. J. Surg. Oncol. 2010; 101:305β314. Β© 2010 WileyβLiss, Inc.
π SIMILAR VOLUMES
Thirty-eight patients with locally advanced breast cancer (Stage HI) were treated over a 3-year period. All patients initially received two cycles of CMF (cyclophosphamide, 100 mg/m2 p.0. dl-14; methotrexate 40mg/m2 intravenously (iv), d l and d8., 5 Fluorouracil 500 mg/m2 iv d l and d8). They were
## Abstract Patients with locally advanced esophageal carcinoma have consistently poor survival following surgery with associated high systemic and localβregional failure rates. Neoadjuvant therapeutic strategies have been employed in an attempt to improve outcome with variable success. Randomized
## Abstract ## BACKGROUND. The objective of the current study was to determine the histologic and molecular changes that occurred in patients with highβrisk, localized prostate cancer (PCa) after neoadjuvant docetaxel chemotherapy. ## METHODS. Patients who had locally advanced PCa (serum preoper